|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 161.00 EUR | +4.41% |
|
+0.12% | +35.29% |
| 03-09 | Hutchmed (China) says Ipsen initiates market withdrawal and recall of Tazverik in China | RE |
| 03-09 | Hutchmed announces update on licensed oncology product Tazverik in China | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 12.28 | 11.75 | 9.02 | 8.22 | 9.6 | |||||
Return on Total Capital | 16.36 | 16.32 | 12.81 | 11.68 | 12.83 | |||||
Return On Equity % | 26.46 | 19.49 | 17.3 | 8.93 | 10.44 | |||||
Return on Common Equity | 26.49 | 19.54 | 17.22 | 8.89 | 10.41 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 82.06 | 83.28 | 82.72 | 82.69 | 80.89 | |||||
SG&A Margin | 34.5 | 32.91 | 34.34 | 32.85 | 29.63 | |||||
EBITDA Margin % | 36.3 | 37.5 | 34.57 | 33.33 | 34.11 | |||||
EBITA Margin % | 33.27 | 34.87 | 32.32 | 31.14 | 32.87 | |||||
EBIT Margin % | 30.53 | 31.57 | 26.04 | 23.49 | 26.14 | |||||
Income From Continuing Operations Margin % | 21.56 | 18.76 | 18.75 | 10 | 11.31 | |||||
Net Income Margin % | 21.56 | 20.55 | 19.49 | 9.68 | 11.29 | |||||
Net Avail. For Common Margin % | 21.56 | 18.79 | 18.66 | 9.96 | 11.29 | |||||
Normalized Net Income Margin | 18.28 | 19.2 | 15.22 | 13.64 | 15.71 | |||||
Levered Free Cash Flow Margin | 13.79 | 21.03 | 25.35 | 2.04 | 16.59 | |||||
Unlevered Free Cash Flow Margin | 14.29 | 21.5 | 25.84 | 2.44 | 17.17 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.64 | 0.6 | 0.55 | 0.56 | 0.59 | |||||
Fixed Assets Turnover | 4.64 | 5.14 | 5.72 | 5.77 | 5.9 | |||||
Receivables Turnover (Average Receivables) | 5.51 | 5.06 | 4.95 | 5.12 | 4.95 | |||||
Inventory Turnover (Average Inventory) | 2.48 | 2.1 | 1.99 | 2.15 | 2.85 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.59 | 1.8 | 1.17 | 1.34 | 1.96 | |||||
Quick Ratio | 1.29 | 1.43 | 0.82 | 1.01 | 1.69 | |||||
Operating Cash Flow to Current Liabilities | 0.74 | 0.73 | 0.53 | 0.61 | 0.79 | |||||
Days Sales Outstanding (Average Receivables) | 66.19 | 72.2 | 73.75 | 71.49 | 73.68 | |||||
Days Outstanding Inventory (Average Inventory) | 146.98 | 174.13 | 183.27 | 170.07 | 127.94 | |||||
Average Days Payable Outstanding | 365.97 | 382.56 | 448.97 | 484.13 | 441.59 | |||||
Cash Conversion Cycle (Average Days) | -152.8 | -136.23 | -191.96 | -242.56 | -239.97 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 34.17 | 23.12 | 12.11 | 12.33 | 22.38 | |||||
Total Debt / Total Capital | 25.47 | 18.78 | 10.8 | 10.98 | 18.28 | |||||
LT Debt/Equity | 28.04 | 19.99 | 8.93 | 9.39 | 19.23 | |||||
Long-Term Debt / Total Capital | 20.9 | 16.24 | 7.96 | 8.36 | 15.72 | |||||
Total Liabilities / Total Assets | 44.99 | 40.5 | 39.52 | 35.06 | 37.49 | |||||
EBIT / Interest Expense | 38.63 | 41.87 | 32.86 | 36.35 | 28.45 | |||||
EBITDA / Interest Expense | 47.49 | 51.53 | 44.99 | 53.26 | 37.89 | |||||
(EBITDA - Capex) / Interest Expense | 43.45 | 47.47 | 40.55 | 45.77 | 34.98 | |||||
Total Debt / EBITDA | 0.84 | 0.63 | 0.39 | 0.42 | 0.71 | |||||
Net Debt / EBITDA | 0.11 | -0.32 | -0.06 | -0.13 | -0.41 | |||||
Total Debt / (EBITDA - Capex) | 0.91 | 0.68 | 0.44 | 0.49 | 0.77 | |||||
Net Debt / (EBITDA - Capex) | 0.12 | -0.35 | -0.06 | -0.15 | -0.44 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 11.65 | 14.84 | 4.75 | 8.11 | 9.92 | |||||
Gross Profit, 1 Yr. Growth % | 12.09 | 13.8 | 4.05 | 8.07 | 10.74 | |||||
EBITDA, 1 Yr. Growth % | 17.1 | 11.74 | 1.07 | 13.05 | 12.47 | |||||
EBITA, 1 Yr. Growth % | 18.02 | 13.63 | 1.98 | 13.64 | 16.02 | |||||
EBIT, 1 Yr. Growth % | 20.63 | 12.44 | -8.76 | 8.77 | 22.29 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 17.82 | -6.19 | 4.7 | -42.36 | 24.41 | |||||
Net Income, 1 Yr. Growth % | 17.99 | 0.31 | -0.65 | -46.32 | 28.22 | |||||
Normalized Net Income, 1 Yr. Growth % | 15.95 | 14.37 | -12.19 | 8.94 | 26.63 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 18.11 | -5.68 | 3.64 | -42.3 | 24.59 | |||||
Accounts Receivable, 1 Yr. Growth % | 18.5 | 12.09 | -0.19 | 10.44 | 12.85 | |||||
Inventory, 1 Yr. Growth % | 2.57 | 29.49 | 1.9 | -1.38 | -15.62 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 0.14 | -10.21 | -1.17 | 15.59 | 0.57 | |||||
Total Assets, 1 Yr. Growth % | 16.09 | 12.37 | 12.62 | 1.84 | 7.75 | |||||
Tangible Book Value, 1 Yr. Growth % | 76.44 | 57.95 | -59.07 | 99.79 | 46.7 | |||||
Common Equity, 1 Yr. Growth % | 29.11 | 22.01 | 14.39 | 9.32 | 3.69 | |||||
Cash From Operations, 1 Yr. Growth % | 17.88 | 8.74 | -10.86 | 5.73 | 24.35 | |||||
Capital Expenditures, 1 Yr. Growth % | 20.02 | 10.15 | 20.29 | 48.97 | -39.24 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -32.97 | 60.67 | 42.53 | -90.18 | 1.81K | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -32.43 | 58.59 | 41.73 | -88.49 | 1.29K | |||||
Dividend Per Share, 1 Yr. Growth % | 20 | 0 | 0 | 16.67 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 5.53 | 8.4 | 9.68 | 6.42 | 9.01 | |||||
Gross Profit, 2 Yr. CAGR % | 5.65 | 9.42 | 8.81 | 6.04 | 7.8 | |||||
EBITDA, 2 Yr. CAGR % | 12.28 | 12.84 | 3.88 | 2.64 | 12.76 | |||||
EBITA, 2 Yr. CAGR % | 12.7 | 14.09 | 5.04 | 3.07 | 14.82 | |||||
EBIT, 2 Yr. CAGR % | 14.22 | 14.58 | -1.43 | -5.67 | 15.33 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 244.79 | 3.86 | -0.9 | -22.32 | -15.32 | |||||
Net Income, 2 Yr. CAGR % | 257.12 | 8.79 | -0.17 | -26.97 | -17.04 | |||||
Normalized Net Income, 2 Yr. CAGR % | 11.77 | 13.19 | -2.55 | -7.76 | 17.46 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 242.71 | 4.25 | -1.13 | -22.67 | -15.21 | |||||
Accounts Receivable, 2 Yr. CAGR % | -0.06 | 15.25 | 5.77 | 4.99 | 11.64 | |||||
Inventory, 2 Yr. CAGR % | 1.25 | 15.25 | 14.87 | 0.25 | -8.78 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -2.37 | -5.18 | -5.8 | 6.88 | 7.82 | |||||
Total Assets, 2 Yr. CAGR % | 7.82 | 14.03 | 12.56 | 7.09 | 4.75 | |||||
Tangible Book Value, 2 Yr. CAGR % | 66.75 | 67.59 | -19.37 | -9.57 | 71.2 | |||||
Common Equity, 2 Yr. CAGR % | 25.36 | 25.14 | 18.26 | 11.82 | 6.47 | |||||
Cash From Operations, 2 Yr. CAGR % | 20.35 | 12.22 | -1.55 | -2.92 | 14.66 | |||||
Capital Expenditures, 2 Yr. CAGR % | -18.53 | 9.96 | 15.11 | 33.75 | -4.86 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 26.09 | 3.7 | 42.45 | -64.82 | -6.2 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 23.94 | 3.45 | 41.32 | -61.97 | -5.63 | |||||
Dividend Per Share, 2 Yr. CAGR % | 9.54 | 9.54 | 0 | 8.01 | 8.01 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.49 | 5.44 | 7.17 | 9.15 | 7.57 | |||||
Gross Profit, 3 Yr. CAGR % | 9.12 | 6.04 | 7.6 | 8.56 | 6.53 | |||||
EBITDA, 3 Yr. CAGR % | 17.67 | 11.08 | 7.13 | 4 | 5.82 | |||||
EBITA, 3 Yr. CAGR % | 16.67 | 11.89 | 8.12 | 4.75 | 7.22 | |||||
EBIT, 3 Yr. CAGR % | 18.14 | 12.39 | 4.29 | -1.78 | 2.86 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 18.66 | 121.61 | 4.14 | -17.28 | -9.12 | |||||
Net Income, 3 Yr. CAGR % | 18.41 | 133.88 | 5.55 | -18.82 | -11.9 | |||||
Normalized Net Income, 3 Yr. CAGR % | 18.08 | 11.34 | 2.09 | -2.73 | 2.52 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 18.61 | 121.09 | 4.05 | -17.38 | -9.34 | |||||
Accounts Receivable, 3 Yr. CAGR % | 6.82 | 3.83 | 9.85 | 7.3 | 7.55 | |||||
Inventory, 3 Yr. CAGR % | 3.39 | 9.91 | 10.61 | 9.18 | -5.35 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 10.93 | -5.06 | -3.86 | 0.85 | 4.74 | |||||
Total Assets, 3 Yr. CAGR % | 14.02 | 9.2 | 13.6 | 8.87 | 7.31 | |||||
Tangible Book Value, 3 Yr. CAGR % | 19.3 | 64.19 | 4.95 | 9.11 | 6.25 | |||||
Common Equity, 3 Yr. CAGR % | 14.33 | 23.99 | 21.53 | 15.2 | 9.04 | |||||
Cash From Operations, 3 Yr. CAGR % | 16.78 | 15.67 | 3.93 | 0.82 | 5.43 | |||||
Capital Expenditures, 3 Yr. CAGR % | -3.25 | -12.56 | 13.3 | 25.37 | 2.82 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 18.04 | 36.64 | 10.74 | -43.94 | 3.5 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 18.63 | 34.49 | 10.46 | -41.15 | 3.81 | |||||
Dividend Per Share, 3 Yr. CAGR % | 6.27 | 6.27 | 6.27 | 5.27 | 5.27 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 12.41 | 9.43 | 7.08 | 5.83 | 7.9 | |||||
Gross Profit, 5 Yr. CAGR % | 13.27 | 10.08 | 7.62 | 6.04 | 7.68 | |||||
EBITDA, 5 Yr. CAGR % | 22.98 | 19.44 | 11.33 | 6.65 | 7.59 | |||||
EBITA, 5 Yr. CAGR % | 22.9 | 19.39 | 11.2 | 7.22 | 8.84 | |||||
EBIT, 5 Yr. CAGR % | 21.33 | 20 | 9.17 | 3.65 | 6.23 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 23.36 | 16.95 | 9.88 | 45.71 | -4.13 | |||||
Net Income, 5 Yr. CAGR % | 23.41 | 18.96 | 10.59 | 46.82 | -4.14 | |||||
Normalized Net Income, 5 Yr. CAGR % | 20.61 | 20.92 | 8.6 | 2.12 | 5.48 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 23.24 | 17.05 | 9.74 | 45.24 | -4.13 | |||||
Accounts Receivable, 5 Yr. CAGR % | 9.19 | 7.67 | 6.4 | 4.29 | 10.56 | |||||
Inventory, 5 Yr. CAGR % | 14.13 | 11.16 | 7.84 | 5.93 | 2.41 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 11.31 | 6.79 | 3.91 | -0.45 | 0.65 | |||||
Total Assets, 5 Yr. CAGR % | 15.62 | 12.79 | 13.36 | 8.38 | 9.97 | |||||
Tangible Book Value, 5 Yr. CAGR % | 3.44 | 41.56 | 2.16 | 29.48 | 27.64 | |||||
Common Equity, 5 Yr. CAGR % | 15.15 | 16.95 | 15.75 | 19.02 | 15.26 | |||||
Cash From Operations, 5 Yr. CAGR % | 23.4 | 18.1 | 8.69 | 7.84 | 8.1 | |||||
Capital Expenditures, 5 Yr. CAGR % | 3.41 | 2.71 | 1.87 | 3.64 | 5.62 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 43.64 | 53.14 | 27.22 | -22.49 | 1.1 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 45.91 | 51.67 | 27.2 | -20.75 | 1.24 | |||||
Dividend Per Share, 5 Yr. CAGR % | 7.14 | 3.71 | 3.71 | 6.96 | 6.96 |
- Stock Market
- Equities
- IPN Stock
- Financials Ipsen
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















